See feature article below on: EXEL

About Broad Street Alerts:

Big opportunities in Small Cap’s

Broadstreetalerts.com recent profiles and track record, 157% in verifiable potential gains for our
members in December 2015 alone.

December 29th, 2015- (NASDAQ: INVT) opened $1.35/share hit a high midday of $2.82/share over 100%
in gains for our members.

December 15th, 2015-(NYSE-MKT: XXII) opened at $1.29 hit a high of $1.54 within 3 days for gains of
19% for our members.

December 2nd, 2015- (NASDAQ: TCCO) opened at $3.25 hit a high of $4.50 within 3 days for 38% gains
for our members.

February 14th, 2015 ETN report on 3x velocity shares Crude oil (NYSEMKT: UWTI) at $15.50/share up
nearly 100% in a little over a month for our members.

These are numbers that make traders drool. Any trader in any market would fall all over themselves to
see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and
verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest
of the small-cap newsletters as the best in business. We know with a large following comes a large
responsibility as we have everyone from institutional investors to the beginner following our profiled
securities in our newsletters. This is something we take very seriously always seeking small cap growth
companies that have both near and long-term potential for our members.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our
VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your
cell phone.

Recently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Exelixis, Inc. (NASDAQ:EXEL).

The most recent broker reports which have been released note that 2 analysts have a rating of “buy”, 1 analysts “outperform”, 2 analysts “hold”, 0 analysts “underperform” and 0 analysts “sell”.

______________________________________________________________________________________________________________________________________
Report on : EXEL
Recent analyst ratings and price targets:

03/01/2016 – Exelixis, Inc. had its “outperform” rating reiterated by analysts at Cowen.

01/19/2016 – Exelixis, Inc. was upgraded to “outperform” by analysts at Leerink Swann. They now have a USD 7 price target on the stock.

01/13/2016 – Exelixis, Inc. had its “outperform” rating reiterated by analysts at William Blair.

07/20/2015 – Exelixis, Inc. had its “neutral” rating reiterated by analysts at Piper Jaffray. They now have a USD 6 price target on the stock.

05/26/2015 – Exelixis, Inc. was downgraded to “hold” by analysts at Zacks.

05/14/2015 – Exelixis, Inc. had its “hold” rating reiterated by analysts at Stifel Nicolaus.

05/05/2014 – Exelixis, Inc. had its “neutral” rating reiterated by analysts at Credit Suisse. They now have a USD 4 price target on the stock.

05/02/2014 – Exelixis, Inc. had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 4 price target on the stock.

01/21/2014 – Exelixis, Inc. had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 11 price target on the stock.

Exelixis, Inc. has a 50 day moving average of 4.07 and a 200 day moving average of 5.12. It has a 52-week low of 2.45 and a 52-week high of 6.81.

The share price of the company (NASDAQ:EXEL) was down -0.26%, with a high of 3.99 during the day and the volume of Exelixis, Inc. shares traded was 4546927.

Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Company’s other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).

Source: Share Trading

There isn’t a day that goes by on Wall Street when certain stocks trading for under $10 a share don’t experience massive spikes higher. Traders savvy enough to follow the low-priced names and trade them with discipline and sod risk management are banking ridiculous coin on a regular basis.

Just take a look at some of the big movers to the upside in the under-$10 complex from Wednesday, including EnerJex Resources (ENRJ) , which soared higher by 32.5%; Joe’s Jeans (JOEZ) , which ripped higher by 23.6%; Entree Gold (EGI) , which spiked higher by 23%; and Alexco Resource (AXU – Get Report) , which jumped higher by 20.5%. You don’t even have to catch the entire move in lower-priced stocks such as these to make outsized returns when trading.

Low-priced stocks are something that I tweet about often. I frequently flag high-probability setups, breakout candidates and low-priced stocks that are acting technically bullish. I like to hunt for low-priced stocks that are showing bullish price and volume trends, since that increases the probability of those stocks heading higher. These setups often produce monster moves higher in very short time frames.

 

Source: The Street

 

BIND Therapeutics Inc (NASDAQ:BIND) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus target price of $7.50 for the company and are anticipating that the company will post ($0.61) EPS for the current quarter, according to Zacks. Zacks has also given BIND Therapeutics an industry rank of 73 out of 265 based on the ratings given to its competitors.

BIND Therapeutics (NASDAQ:BIND) opened at 1.92 on Thursday. The company’s 50-day moving average price is $1.66 and its 200 day moving average price is $3.27. BIND Therapeutics has a 52-week low of $1.14 and a 52-week high of $8.10. The firm’s market capitalization is $39.90 million.

BIND Therapeutics (NASDAQ:BIND) last issued its earnings results on Tuesday, March 15th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.12. The company earned $6.40 million during the quarter, compared to analyst estimates of $3.35 million. Equities analysts predict that BIND Therapeutics will post ($1.89) earnings per share for the current fiscal year.

BIND has been the topic of a number of research analyst reports. Zacks Investment Research upgraded BIND Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research report on Wednesday, January 6th. Oppenheimer restated an “outperform” rating on shares of BIND Therapeutics in a research report on Wednesday, February 17th. JPMorgan Chase & Co. decreased their price target on BIND Therapeutics from $9.00 to $6.00 and set a “market outperform” rating on the stock in a research report on Wednesday, March 9th. Finally, JMP Securities increased their price target on BIND Therapeutics from $9.00 to $25.00 and gave the stock a “market outperform” rating in a research report on Tuesday, December 15th.

BIND Therapeutics, Inc is a clinical-stage nano-medicine platform company. The Company is engaged in developing a pipeline of Accurins. The Company utilizes its Medicinal Nano-engineering platform to develop a pipeline of Accurins in oncology. The Company’s products include BIND-014 and BIND-510. The Company’s lead drug candidate BIND-014 is a prostate-specific membrane antigen (NASDAQ:BIND)-targeted Accurin that contains docetaxel, a clinically validated cancer chemotherapy drug.

Recently stock market analysts have updated their consensus ratings on shares of Azure Midstream Partners, LP (NYSE:AZUR).

The latest broker reports which have been released state 1 analyst has a rating of “buy”, 0 analysts “outperform”, 0 analysts “hold”, 0 analysts “underperform” and 1 analysts “sell”.

Most recent broker ratings

01/28/2016 – Azure Midstream Partners, LP was downgraded to “sell” by analysts at Stifel Nicolaus.

01/11/2016 – Azure Midstream Partners, LP was downgraded to “market perform” by analysts at FBR Capital Markets. They now have a USD 3.25 price target on the stock.

11/14/2015 – Azure Midstream Partners, LP was downgraded to “underperform” by analysts at Oppenheimer.

10/07/2015 – Azure Midstream Partners, LP had its “buy” rating reiterated by analysts at Janney Montgomery Scott. They now have a USD 30 price target on the stock.

Azure Midstream Partners, LP has a 50 day moving average of 1.84 and a 200 day moving average of 5.41. The stock’s market capitalization is 30.48M, it has a 52-week low of 1.28 and a 52-week high of 23.89.

The share price of the company (NYSE:AZUR) was down -4.11%, with a high of 1.49 during the day and the volume of Azure Midstream Partners, LP shares traded was 91595.

 

Source: Risers and Fallers